Myriad Genetics (MYGN) Q4 2025 Earnings Transcript

The Motley Fool

by newsfeedback@fool.com (Motley Fool Transcribing)

February 23, 2026

AI-Generated Deep Dive Summary

Myriad Genetics (MYGN) reported steady financial performance for Q4 2025, with total revenue reaching $209.8 million, consistent with the prior year and within its preannounced range. Despite a slight decline in average revenue per test, driven by challenges from payer policies like UnitedHealthcare’s impact on GeneSight, the company delivered strong growth in key areas. MyRisk oncology test volumes grew 14% for affected patients and 11% for unaffected markets, while Prolaris test volume increased 12%, contributing to a 16% revenue rise. Adjusted EPS improved to $0.04, marking a positive shift from the prior year. These results highlight Myriad’s ability to maintain stability amid external pressures. The company faced challenges in its prenatal portfolio, with volumes declining year over year due to disruptions in Q2 order management and ongoing recovery efforts. However, GeneSight demonstrated resilience, with volume growing 9% and reaching over 38,000 ordering clinicians. Adjusted gross margin dipped by 190 basis points to 70%, primarily due to payer policy changes affecting GeneSight. Myriad also reduced adjusted operating expenses by $7 million year over year through strategic cost control in commercial and R&D programs, resulting in an adjusted EBITDA of $14.3 million for the quarter. Looking ahead, Myriad Genetics reaffirmed its 2026 guidance, projecting revenue between $860 million and $880 million with a targeted adjusted gross margin of 68%–69%. The company is poised to launch several new products in 2026, including an expanded MyRisk panel, the FirstGene multiple prenatal screen, and an AI-enabled Prolaris prostate cancer test. However, revenue contributions from its MRD (Minimal Residual Disease) tests are expected to remain minimal in 2026 due to ongoing regulatory review cycles

Verticals

financeinvesting

Originally published on The Motley Fool on 2/23/2026